These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 16518754)

  • 1. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.
    Morishima C; Polyak SJ; Ray R; Doherty MC; Di Bisceglie AM; Malet PF; Bonkovsky HL; Sullivan DG; Gretch DR; Rothman AL; Koziel MJ; Lindsay KL;
    J Infect Dis; 2006 Apr; 193(7):931-40. PubMed ID: 16518754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).
    Pilli M; Zerbini A; Penna A; Orlandini A; Lukasiewicz E; Pawlotsky JM; Zeuzem S; Schalm SW; von Wagner M; Germanidis G; Lurie Y; Esteban JI; Haagmans BL; Hezode C; Lagging M; Negro F; Homburger Y; Neumann AU; Ferrari C; Missale G;
    Gastroenterology; 2007 Oct; 133(4):1132-43. PubMed ID: 17919489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.
    Aghemo A; Rumi MG; Colombo M
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):925-35. PubMed ID: 19803700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin.
    Dal Pero F; Tang KH; Gerotto M; Bortoletto G; Paulon E; Herrmann E; Zeuzem S; Alberti A; Naoumov NV
    J Infect Dis; 2007 Oct; 196(7):998-1005. PubMed ID: 17763320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of hepatitis C virus infection].
    Zeuzem S
    Praxis (Bern 1994); 2005 May; 94(18):721-6. PubMed ID: 15938383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
    Ramos B; Núñez M; Rendón A; Berdún MA; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Barreiro P; Romero M; Labarga P; Guardiola JM; Garcia-Samaniego J; Soriano V
    J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
    Mukherjee S; Lyden E
    Hepatogastroenterology; 2006; 53(70):561-5. PubMed ID: 16995462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder.
    Di Bisceglie AM; Fan X; Chambers T; Strinko J
    J Med Virol; 2006 Apr; 78(4):446-51. PubMed ID: 16566033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
    Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
    J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C).
    Sherman KE; Andersen JW; Butt AA; Umbleja T; Alston B; Koziel MJ; Peters MG; Sulkowski M; Goodman ZD; Chung RT;
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):597-605. PubMed ID: 20921898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of antiviral therapy on the cellular immune response in acute hepatitis C.
    Rahman F; Heller T; Sobao Y; Mizukoshi E; Nascimbeni M; Alter H; Herrine S; Hoofnagle J; Liang TJ; Rehermann B
    Hepatology; 2004 Jul; 40(1):87-97. PubMed ID: 15239090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients.
    Giannini EG; Basso M; Bazzica M; Contini P; Marenco S; Savarino V; Picciotto A
    J Viral Hepat; 2010 Aug; 17(8):563-8. PubMed ID: 19840364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus guidelines for the management of hepatitis C infection.
    Consensus Guidelines Committee for the Management of Hepatitis C Infection
    Saudi Med J; 2003 Jul; 24 Suppl 2():S99-118. PubMed ID: 25121186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
    Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
    Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.